Abstract
While there are many underlying causes of thrombocytopenia to consider, some causes are rare and easily overlooked. Solve it!
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Kutny MA, Rajpurkar M, Alonzo TA, Gerbing MB, Gamis AS, Feusner JH, Gregory J. Evaluation of ISTH DIC score to predict significant bleeding and thrombosis events in pediatric acute promyelocytic leukemia; a report from the children’s oncology group AAML0631 trial. Blood. 2014;124(21):3669.
Hod EA, Francis RO. Noninfectious complications of blood transfusion. In: Cohn CS, Delaney M, Johnson ST, Katz LM, editors. Technical manual. 20th ed. Bethesda: AABB; 2020. p. 650–2.
Peterson JA, McFarland JG, Curtis BR, Aster RH. Neonatal alloimmune thrombocytopenia: pathogenesis, diagnosis and management. Br J Haematol. 2013;161(1):3–14.
Hawkins J, Aster RH, Curtis BR. Post-transfusion purpura: current perspectives. J Blood Med. 2019;10:405–15.
Carlsson LE, Greinacher A, Spitzer C, Walther R, Kessler C. Polymorphisms of the human platelet antigens HPA-1, HPA-2, HPA-3, and HPA-5 on the platelet receptors for fibrinogen (GPIIb/IIIa), von Willebrand factor (GPIb/IX), and collagen (GPIa/IIa) are not correlated with an increased risk for stroke. Stroke. 1997;28:1392–5.
Storch EK, Cushing MM. Posttransfusion purpura. In: Shaz BH, Hillyer CD, Gil MR, editors. Transfusion medicine and hemostasis. 3rd ed. Dordrecht: Elsevier Science; 2018. p. 419–21.
Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, et al. Guidelines on the use of therapeutic apheresis in clinical practice—evidence-based approach from the Writing Committee of the American Society for Apheresis: the eighth special issue. J Clin Apher. 2019;34:287.
Centers for disease Control and Prevention. National healthcare safety network biovigilance component, hemovigilance module surveillance protocol v2.6. Atlanta, GA: National Healthcare Safety Network; 2021. https://www.cdc.gov/nhsn/PDFs/Biovigilance/BV-HV-protocol-current.pdf. Accessed 4 Jan 2022.
Chung K-W, Harvey A, Basavaraju SV, Kuehnert MJ. How is national recipient hemovigilance conducted in the United States? Transfusion. 2015;55:703–7.
Serrarans-Janssen JM, Semmekrot BA, Novotny VM, Porcelijin L, Lotgering FK, Delemarre FM, Steegers EA. Fetal/neonatal allo-immune thrombocytopenia (FNAIT): past, present, and future. Obstet Gynecol Surv. 2008;63(4):239–52.
Further Reading
Hawkins J, Aster RH, Curtis BR. Post-transfusion purpura: current perspectives. J Blood Med. 2019;10:405–15.
Storch EK, Cushing MM. Posttransfusion purpura. In: Shaz BH, Hillyer CD, Gil MR, editors. Transfusion medicine and hemostasis. 3rd ed. Dordrecht: Elsevier Science; 2018. p. 419–21.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Friedman, M.T., West, K.A., Bizargity, P., Annen, K., Gur, H.D., Hilbert, T. (2023). Cruising for a Bruising. In: Immunohematology, Transfusion Medicine, Hemostasis, and Cellular Therapy. Springer, Cham. https://doi.org/10.1007/978-3-031-14638-1_36
Download citation
DOI: https://doi.org/10.1007/978-3-031-14638-1_36
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-14637-4
Online ISBN: 978-3-031-14638-1
eBook Packages: MedicineMedicine (R0)